

New Products - Giotrif

Giotrif (**afatinib (as afatinib dimaleate)**) is an irreversible ErbB family blocker. Afatinib covalently binds to and irreversibly blocks signalling from all homo- and heterodimers formed by the ErbB family members EGFR (epidermal growth factor receptor, ErbB1), HER2 (human epidermal growth factor receptor 2, ErbB2), ErbB3 and ErbB4. It is indicated in monotherapy for treatment (1st line or after cytotoxic chemotherapy failure) of advanced or metastatic non-squamous non-small cell carcinoma of the lung (tumours must have EGFR exon 19 deletions or L858R substitution mutations). Giotrif is available as 20, 30, 40 and 50 mg tablets in packs of 28's.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.